Increased Serum Chemerin Levels in Diabetic Retinopathy of Type 2 Diabetic Patients

References

• Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948–959
   PubMed Web of Science ®Google Scholar
• Negi A, Vernon SA. An overview of the eye in diabetes. J R Soc Med 2003;96:266–272
   PubMed Web of Science ®Google Scholar
• Tielsch JM, Sommer A, Witt K, Katz J, Royall RM. Blindness and visual impairment in an American urban population. The Baltimore Eye Survey. Arch Ophthalmol 1990;108:286–290
   PubMed Web of Science ®Google Scholar
• Simo R, Carrasco E, Garcia-Ramirez M, Hernandez C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2006;2:71–98
   PubMedGoogle Scholar
• Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 2002;86:363–365
   PubMed Web of Science ®Google Scholar
• Patel JI, Tombran-Tink J, Hykin PG, Gregor ZJ, Cree IA. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: implications for structural differences in macular profiles. Exp Eye Res 2006;82:798–806
   PubMed Web of Science ®Google Scholar
• Abu EA, Struyf S, Kangave D, Geboes K, Van Damme J. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw 2006;17:155–165
   PubMed Web of Science ®Google Scholar
• Hernandez C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simo R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2005;22:719–722
   PubMed Web of Science ®Google Scholar
• Ozturk BT, Bozkurt B, Kerimoglu H, Okka M, Kamis U, Gunduz K. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol Vis 2009;15:1906–1914
   PubMed Web of Science ®Google Scholar
• Simo R, Hernandez C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 2008;51:1574–1580
   PubMed Web of Science ®Google Scholar
• Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LE. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 2009;50:1329–1335
   PubMed Web of Science ®Google Scholar
• Wirostko B, Wong TY, Simo R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res 2008;27:608–621
   PubMed Web of Science ®Google Scholar
• Jiang Y, Liang X, Li X, Tao Y, Wang K. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol 2009;87:736–740
   PubMed Web of Science ®Google Scholar
• Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282:28175–28188
   PubMed Web of Science ®Google Scholar
• Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007;148:4687–4694
   PubMed Web of Science ®Google Scholar
• Kaur J, Adya R, Tan BK, Chen J, Randeva HS. Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun 2010;391:1762–1768
   PubMed Web of Science ®Google Scholar
• Zakareia FA. Correlation of peripheral arterial blood flow with plasma chemerin and VEGF in diabetic peripheral vascular disease. Biomark Med 2012;6:81–87
   PubMed Web of Science ®Google Scholar
• El-Mesallamy HO, El-Derany MO, Hamdy NM. Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med 2011;28:1194–1200
   PubMed Web of Science ®Google Scholar
• Lin X, Tang X, Jiang Q, Liu Q, Lin Z, Lin J, et al. Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with type 2 diabetes. Clin Lab 2012;58:539–544
   PubMed Web of Science ®Google Scholar
• Yu S, Zhang Y, Li MZ, Xu H, Wang Q, Song J, et al. Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients. Chin Med J (Engl) 2012;125:3440–3444
   PubMed Web of Science ®Google Scholar
• Wilkinson CP, Ferris FR, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003;110:1677–1682
   PubMed Web of Science ®Google Scholar
• Wang LY, Wei L, Yu HY, Zhang Y, Jia WP. [Relationship of serum chemerin to obesity and type 2 diabetes mellitus]. Zhonghua Yi Xue Za Zhi 2009;89:235–238
   PubMedGoogle Scholar
• Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie AG, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab 2009;94:3085–3088
   PubMed Web of Science ®Google Scholar
• Hu W, Feng P. Elevated serum chemerin concentrations are associated with renal dysfunction in type 2 diabetic patients. Diabetes Res Clin Pract 2011;91:159–163
   PubMed Web of Science ®Google Scholar
• Coimbra S, Brandao PJ, Santos-Silva A, Neuparth MJ. Adiponectin, leptin, and chemerin in elderly patients with type 2 diabetes mellitus: a close linkage with obesity and length of the disease. Biomed Res Int 2014;2014:701915
   PubMed Web of Science ®Google Scholar
• Pfau D, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care 2010;33:171–173
   PubMed Web of Science ®Google Scholar
• Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population – a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152:217–221
   PubMed Web of Science ®Google Scholar
• Yang M, Yang G, Dong J, Liu Y, Zong H, Liu H, et al. Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med 2010;58:883–886
   PubMed Web of Science ®Google Scholar
• Kloting N, Fasshauer M, Dietrich A, Kovacs P, Schon MR, Kern M, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 2010;299:E506–E515
   PubMed Web of Science ®Google Scholar
• Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 2009;161:339–344
   PubMed Web of Science ®Google Scholar
• Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 2010;72:342–348
   PubMed Web of Science ®Google Scholar
• Ailhaud G. Adipose tissue as a secretory organ: from adipogenesis to the metabolic syndrome. C R Biol 2006;329:570–577, 653–655
   PubMed Web of Science ®Google Scholar
• Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M, et al. Chemerin – a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun 2007;362:1013–1018
   PubMed Web of Science ®Google Scholar
• van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study. Diabetes Care 2002;25:1320–1325
   PubMed Web of Science ®Google Scholar
• Cusick M, Chew EY, Chan CC, Kruth HS, Murphy RP, Ferris FR. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology 2003;110:2126–2133
   PubMed Web of Science ®Google Scholar
• Chew EY, Klein ML, Ferris FR, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079–1084
   PubMed Web of Science ®Google Scholar
• Wang D, Yuan GY, Wang XZ, Jia J, Di LL, Yang L, et al. Plasma chemerin level in metabolic syndrome. Genet Mol Res 2013;12:5986–5991
   PubMed Web of Science ®Google Scholar
• Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003;198:977–985
   PubMed Web of Science ®Google Scholar
• Parolini S, Santoro A, Marcenaro E, Luini W, Massardi L, Facchetti F, et al. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood 2007;109:3625–3632
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Qureshi AR, Anderstam B, Heimburger O, Barany P, Lindholm B, et al. Clinical importance of an elevated circulating chemerin level in incident dialysis patients. Nephrol Dial Transplant 2010;25:4017–4023
   PubMed Web of Science ®Google Scholar
• Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull 2011;34:307–310
   PubMed Web of Science ®Google Scholar
• Bozaoglu K, Curran JE, Stocker CJ, Zaibi MS, Segal D, Konstantopoulos N, et al. Chemerin, a novel adipokine in the regulation of angiogenesis. J Clin Endocrinol Metab 2010;95:2476–2485
   PubMed Web of Science ®Google Scholar
• Kasai A, Ishimaru Y, Kinjo T, Satooka T, Matsumoto N, Yoshioka Y, et al. Apelin is a crucial factor for hypoxia-induced retinal angiogenesis. Arterioscler Thromb Vasc Biol 2010;30:2182–2187
   PubMed Web of Science ®Google Scholar
• Parolini S, Santoro A, Marcenaro E, Luini W, Massardi L, Facchetti F, et al. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood 2007;109:3625–3632
   PubMed Web of Science ®Google Scholar
• Shen W, Tian C, Chen H, Yang Y, Zhu D, Gao P, et al. Oxidative stress mediates chemerin-induced autophagy in endothelial cells. Free Radic Biol Med 2013;55:73–82
   PubMed Web of Science ®Google Scholar
• Fulop P, Seres I, Lorincz H, Harangi M, Somodi S, Paragh G. Association of chemerin with oxidative stress, inflammation and classical adipokines in non-diabetic obese patients. J Cell Mol Med 2014;18:1313–1320
   PubMed Web of Science ®Google Scholar